Published in Cytotherapy on January 01, 2009
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Clinical applications of mesenchymal stem cells in soft tissue augmentation. Aesthet Surg J (2010) 1.54
Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest (2010) 1.44
Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol (2013) 1.29
Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair (2011) 1.13
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 1.12
Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation. Biol Blood Marrow Transplant (2010) 1.04
miR-146a-5p circuitry uncouples cell proliferation and migration, but not differentiation, in human mesenchymal stem cells. Nucleic Acids Res (2013) 1.02
Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res (2015) 1.00
A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. Cytotherapy (2014) 0.99
The effect of mesenchymal stromal cell-hyaluronic acid hydrogel constructs on immunophenotype of macrophages. Tissue Eng Part A (2011) 0.97
Mesenchymal stem cells: From bench to bedside. World J Stem Cells (2010) 0.97
Proteomic definitions of mesenchymal stem cells. Stem Cells Int (2011) 0.96
Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Res (2011) 0.96
Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol (2011) 0.96
Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. Stem Cells (2014) 0.93
Gene expression profiles of human adipose tissue-derived mesenchymal stem cells are modified by cell culture density. PLoS One (2014) 0.92
Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy (2014) 0.88
Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr Opin Hematol (2010) 0.88
Recent advances in bone regeneration using adult stem cells. World J Stem Cells (2015) 0.86
The role of recipient T cells in mesenchymal stem cell-based tissue regeneration. Int J Biochem Cell Biol (2012) 0.86
Local delivery of allogeneic bone marrow and adipose tissue-derived mesenchymal stromal cells for cutaneous wound healing in a porcine model. J Tissue Eng Regen Med (2013) 0.84
Adipose tissue-derived mesenchymal stem cells differentiated into hepatocyte-like cells in vivo and in vitro. Mol Med Rep (2014) 0.84
Effects of Oxidative Stress on Mesenchymal Stem Cell Biology. Oxid Med Cell Longev (2016) 0.84
Biologic and immunomodulatory properties of mesenchymal stromal cells derived from human pancreatic islets. Cytotherapy (2012) 0.81
Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA J (2010) 0.81
Human embryonic stem cell-derived mesenchymal stromal cells. Transfusion (2011) 0.80
Stem cell-based strategies for the treatment of type 1 diabetes mellitus. Expert Opin Biol Ther (2010) 0.80
Regulation of Immunity via Multipotent Mesenchymal Stromal Cells. Acta Naturae (2012) 0.79
Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model. Exp Hematol (2013) 0.79
Thiol-ene Michael-type formation of gelatin/poly(ethylene glycol) biomatrices for three-dimensional mesenchymal stromal/stem cell administration to cutaneous wounds. Acta Biomater (2013) 0.79
Systemic infusion of mesenchymal stem cells improves cell-based bone regeneration via upregulation of regulatory T cells. Tissue Eng Part A (2015) 0.79
Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study. Oncotarget (2016) 0.77
Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion. Cytotherapy (2016) 0.77
Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. Tissue Eng Part B Rev (2014) 0.75
Peripheral blood stem cell transplants do not result in endometrial stromal engraftment. Fertil Steril (2012) 0.75
Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review. Immune Netw (2017) 0.75
Influence of a dual-injection regimen, plerixafor and CXCR4 on in utero hematopoietic stem cell transplantation and engraftment with use of the sheep model. Cytotherapy (2014) 0.75
Promoting the recovery of injured liver with poly (3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) scaffolds loaded with umbilical cord-derived mesenchymal stem cells. Tissue Eng Part A (2014) 0.75
Application of the Multiplicative-Additive Model in the Bone Marrow Transplantation Survival Data Including Competing Risks. Iran J Public Health (2015) 0.75
Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Korean J Physiol Pharmacol (2015) 0.75
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng (2001) 20.65
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 12.59
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Mesenchymal stem cells. J Orthop Res (1991) 10.98
Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med (1999) 9.73
Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 6.97
Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol (2007) 6.63
Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol (2004) 5.82
Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation (1968) 5.52
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol (2003) 5.35
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 5.33
Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol (2005) 5.31
Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation (2003) 5.07
The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs (2001) 4.31
Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells (2004) 3.98
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol (2000) 3.94
From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol (2007) 3.87
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant (2002) 3.24
Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol (2005) 3.12
Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells (2006) 3.02
Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) (2005) 3.00
Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells (2004) 2.88
Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant (2008) 2.86
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant (2005) 2.82
Mesenchymal stem cells: paradoxes of passaging. Exp Hematol (2004) 2.52
Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol (2007) 2.50
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation (2003) 2.49
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood (2002) 2.43
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant (1995) 2.35
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia (2007) 2.25
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes (2008) 2.25
Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica (2003) 2.23
Mesenchymal stem cells: progress toward promise. Cytotherapy (2005) 2.19
T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci (2005) 2.07
Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol (2002) 2.05
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.93
Mesenchymal stromal cells. Curr Opin Hematol (2006) 1.88
Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation (2005) 1.85
"Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clin Pharmacol Ther (2007) 1.85
Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol (2005) 1.83
Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy (2009) 1.81
Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood (2004) 1.65
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy (2006) 1.64
Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood (2006) 1.63
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant (2008) 1.61
Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol (1999) 1.55
The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy (2008) 1.52
Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol (2007) 1.50
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood (2004) 1.47
Mesenchymal stromal cells: Tissue repair and immune modulation. Cytotherapy (2006) 1.47
Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc (2007) 1.44
Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol (2007) 1.42
Mesenchymal stem cells for cardiac regenerative therapy. Handb Exp Pharmacol (2007) 1.40
Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy (2004) 1.40
Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol (2002) 1.39
Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. Br J Haematol (2008) 1.39
Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg (2008) 1.38
Effects of plating density and culture time on bone marrow stromal cell characteristics. Exp Hematol (2008) 1.36
Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant (2007) 1.31
Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis (2007) 1.28
Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy (2009) 1.27
Mesenchymal stem cells: heading into the clinic. Bone Marrow Transplant (2001) 1.26
Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy (2009) 1.25
Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opin Hematol (2000) 1.22
Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res (2006) 1.20
Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma (2007) 1.18
Role of the osteoblast lineage in the bone marrow hematopoietic niches. J Bone Miner Res (2009) 1.13
The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. Cytotherapy (2007) 1.08
OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr Opin Investig Drugs (2006) 1.07
Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol (2007) 1.02
Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc (2007) 1.00
Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant (2007) 1.00
Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation (2007) 0.99
Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy (2009) 0.97
Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds. Cytotherapy (2008) 0.95
Cell therapy for disorders of bone. Cytotherapy (2009) 0.88
Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant (2008) 0.86
Prophylaxis of acute GVHD: manipulate the graft or the environment? Best Pract Res Clin Haematol (2008) 0.82
BM-derived cell therapies for cardiovascular disease. Cytotherapy (2007) 0.78
Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor. Bone Marrow Transplant (2009) 0.77
Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol (2009) 3.07
Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev (2014) 2.27
Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood (2005) 2.27
Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood (2004) 1.99
Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol (2008) 1.80
AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood (2006) 1.79
Clinical applications of mesenchymal stem cells in soft tissue augmentation. Aesthet Surg J (2010) 1.54
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood (2012) 1.51
Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol Ther (2004) 1.33
Mesenchymal stem cell therapy for nonhealing cutaneous wounds. Plast Reconstr Surg (2010) 1.24
Simultaneous generation of CD34+ primitive hematopoietic cells and CD73+ mesenchymal stem cells from human embryonic stem cells cocultured with murine OP9 stromal cells. Exp Hematol (2007) 1.14
Characterization of mesenchymal stem cells from human vocal fold fibroblasts. Laryngoscope (2010) 1.14
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol (2012) 1.12
Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg (2010) 1.08
Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model. Cytotherapy (2009) 1.05
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer (2010) 1.02
The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood (2004) 0.99
Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model. Oncogene (2002) 0.98
The effect of mesenchymal stromal cell-hyaluronic acid hydrogel constructs on immunophenotype of macrophages. Tissue Eng Part A (2011) 0.97
Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma (2013) 0.93
Cell encapsulating biomaterial regulates mesenchymal stromal/stem cell differentiation and macrophage immunophenotype. Stem Cells Transl Med (2012) 0.92
In vitro characterization of macrophage interaction with mesenchymal stromal cell-hyaluronan hydrogel constructs. J Biomed Mater Res A (2013) 0.89
Clinical applications of mesenchymal stem cells in laryngotracheal reconstruction. Curr Stem Cell Res Ther (2010) 0.84
Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood (2004) 0.82
Biologic and immunomodulatory properties of mesenchymal stromal cells derived from human pancreatic islets. Cytotherapy (2012) 0.81
Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes. Biol Blood Marrow Transplant (2010) 0.81
Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease. Biol Blood Marrow Transplant (2013) 0.81
Mesenchymal stromal cells are present in the heart and promote growth of adult stem cells in vitro. Cytotherapy (2010) 0.81
Comparative analysis of adipose-derived mesenchymal stem cells isolated from abdominal and breast tissue. Aesthet Surg J (2013) 0.81
Brief report: Mesenchymal stromal cell atrophy in coculture increases aggressiveness of transformed cells. Stem Cells (2013) 0.80
An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy. Clin Transl Sci (2014) 0.80
Biomaterial-mesenchymal stem cell constructs for immunomodulation in composite tissue engineering. Tissue Eng Part A (2014) 0.79
Generation of CD34+ cells from human embryonic stem cells using a clinically applicable methodology and engraftment in the fetal sheep model. Exp Hematol (2013) 0.79
Thiol-ene Michael-type formation of gelatin/poly(ethylene glycol) biomatrices for three-dimensional mesenchymal stromal/stem cell administration to cutaneous wounds. Acta Biomater (2013) 0.79
Current applications of mesenchymal stem cells for tissue replacement in otolaryngology-head and neck surgery. Am J Stem Cells (2012) 0.79
Comparison of breast and abdominal adipose tissue mesenchymal stromal/stem cells in support of proliferation of breast cancer cells. Cancer Invest (2013) 0.79
Mesenchymal stem cell therapies: the quest for fine-tuning. Exp Dermatol (2014) 0.78
MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol (2012) 0.78
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2012) 0.78
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol (2014) 0.77
Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program. Transfusion (2014) 0.77
Mesenchymal Stromal/Stem Cell and Minocycline-Loaded Hydrogels Inhibit the Growth of Staphylococcus aureus that Evades Immunomodulation of Blood-Derived Leukocytes. AAPS J (2015) 0.77
Fibroblasts and Mesenchymal Stromal/Stem Cells Are Phenotypically Indistinguishable. Acta Haematol (2016) 0.76
Generation of mesenchymal stromal cells from HOXB4-expressing human embryonic stem cells. Cytotherapy (2009) 0.75